<DOC>
	<DOC>NCT02963727</DOC>
	<brief_summary>Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis</brief_summary>
	<brief_title>Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis</brief_title>
	<detailed_description>Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Severe KOA stage III or IV by Laurance &amp; Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint. Willing to participate by signing the informed consent 1. Sublaxation beyond 20 degrees of the bones of the knee joint 2. Oral anticoagulants or heparin therapy 3. Heart failure or arrhythmia 4. Body Mass Index &gt; 35 5. Uncontrolled Diabetes Mellitus. 6. Evidence of Infectious Diseases. 7. Active infection 8. Malignancy 9. Pregnancy 10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000. 11. Unreliable patients 12. Nonresident in Jordan</criteria>
	<gender>All</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>osteoarthrosis</keyword>
	<keyword>Knee</keyword>
	<keyword>Wharton Jelly</keyword>
</DOC>